|Bid||23.10 x 300|
|Ask||23.12 x 200|
|Day's Range||22.90 - 23.41|
|52 Week Range||11.41 - 24.88|
|PE Ratio (TTM)||-16.86|
|Earnings Date||Aug 1, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||24.50|
Nektar neared a breakout on a deal with Lilly for a drug designed to fight autoimmune and inflammatory conditions.
The therapy could treat an underlying disease but is very early in development.
NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.